{"DataElement":{"publicId":"2946963","version":"1","preferredName":"Sorafenib Agent Course Total Dose","preferredDefinition":"the total dose of the course or cycle of sorafenib (a synthetic compound targeting growth signaling and angiogenesis).","longName":"SOR_AGT_C_TTL_DOSE","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2946957","version":"1","preferredName":"Sorafenib Agent Course","preferredDefinition":"information related to the course or cycle of sorafenib (a synthetic compound targeting growth signaling and angiogenesis).","longName":"SORA_AGT_CRSE","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2946955","version":"1","preferredName":"Sorafenib Agent","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C61948:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A708AC-3A23-83AD-E040-BB89AD437C12","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-28","modifiedBy":"ONEDATA","dateModified":"2009-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177604","version":"1","preferredName":"Course","preferredDefinition":"Course; a connected series of events or actions or developments","longName":"Course","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51B4-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A708AC-3A31-83AD-E040-BB89AD437C12","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188705","version":"1","preferredName":"Agent Total Dose","preferredDefinition":"the total dose of an agent.","longName":"AGT_TTL_DOSE","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207921","version":"1","preferredName":"Total Dose","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.:The amount of medicine taken, or radiation given, at one time.","longName":"C25304:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3542-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E53FB579-C11C-0A0E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"3298577","version":"1","longName":"Hepatobiliary","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104993","version":"1","longName":"RTOG-1112","context":"NRG"}]}],"AlternateNames":[{"name":"SOR_AGT_C_TTL_DOSE","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Total dose of sorafenib recei","type":"Preferred Question Text","description":"Total dose of sorafenib received this cycle","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"74A708AC-3AAA-83AD-E040-BB89AD437C12","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}